A Pilot Study of the Addition of Bevacizumab to VOIT Regimen for Relapsed/Refractory Pediatric Solid Tumors

NCT00786669 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: Bevacizumab
DRUG: Temozolomide
DRUG: Vincristine
DRUG: Irinotecan
DRUG: Cefixime

Sponsor

Children's Hospital Medical Center, Cincinnati